Program
afimkibart
Also written as “Afimkibart”, “PF-06480605” and “RO7790121”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Dermatitis, Atopic · Arthritis, Rheumatoid, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1814 open or running | phase 3since Sep 6, 2024 | Nov 14, 2013 | Dec 31, 2026phase 2 · NCT05910528 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6631 afimkibart
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Pfizer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 14, 2013.
- Sep 12, 2019Phase 2 study in Moderate to Severe Ulcerative ColitisNCT04090411 · 246 enrolled · United States, Australia, Belgium and more
- Jan 22, 2020Phase 1 study in HealthyNCT04269538 · 16 enrolled · Japan
- Jun 9, 2023Phase 2 study in Crohn DiseaseNCT05910528 · 21 enrolled · United States, Belgium, France and more
- Sep 6, 20242 phase 3 studies in Moderately to Severely Active Ulcerative ColitisNCT06589986, NCT06588855
- Feb 6, 20252 phase 3 studies in Moderately to Severely Active Crohns DiseaseNCT06819891, NCT06819878
- Mar 4, 2025Phase 2 study in Dermatitis, AtopicNCT06863961 · 162 enrolled · United States, Brazil, Canada and more
- Mar 18, 2025Phase 1 study in MASHNCT06903065 · 56 enrolled · United States, Mexico, Puerto Rico
- Aug 15, 2025Phase 2 study in Arthritis, RheumatoidNCT07137598 · 160 planned · United States, Argentina, Belgium and more
- Aug 28, 2025Phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT07158242 · 100 planned · United States, Australia, Brazil and more
- Oct 30, 2025Phase 2 study in Dermatitis, AtopicNCT07223697 · 120 enrolled · United States, Brazil, Canada and more
- Dec 19, 2025Phase 3 study in Moderately to Severely Active Crohns DiseaseNCT07298421 · 100 planned · United States, Australia, Brazil and more
- May 27, 2026Phase 2 study in Arthritis, RheumatoidNCT07620392 · 120 planned · United States, Brazil, Poland
- Jun 19, 2026Phase 1 study in Active Ulcerative ColitisNCT07665723 · 25 planned · United States, Belgium, Germany and more
- Sep 10, 2026Phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT07846683 · 350 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Crohn DiseaseNCT05910528
- Jan 30, 2027Primary completion: phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT06589986
- Apr 17, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07137598
- Jul 31, 2027Primary completion: phase 1 study in Active Ulcerative ColitisNCT07665723
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07846683Moderately to Severely Active Ulcerative Colitis · United States | 3 | Recruiting | May 31, 2028 | 350 |
| NCT07665723Active Ulcerative Colitis · United States, Belgium, Germany and more | 1 | Recruiting | Jul 31, 2027 | 25 |
| NCT07620392Arthritis, Rheumatoid · United States, Brazil, Poland | 2 | Recruiting | Jul 8, 2033 | 120 |
| NCT07298421Moderately to Severely Active Crohns Disease · United States, Australia, Brazil and more | 3 | Recruiting | May 31, 2030 | 100 |
| NCT07223697Dermatitis, Atopic · United States, Brazil, Canada and more | 2 | Active, not recruiting | Mar 1, 2033 | 120 |
| NCT07158242Moderately to Severely Active Ulcerative Colitis · United States, Australia, Brazil and more | 3 | Recruiting | Mar 31, 2030 | 100 |
| NCT07137598Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 2 | Recruiting | Apr 17, 2027 | 160 |
| NCT06903065MASH · United States, Mexico, Puerto Rico | 1 | Active, not recruiting | Sep 24, 2026 | 56 |
| NCT06863961Dermatitis, Atopic · United States, Brazil, Canada and more | 2 | Active, not recruiting | Jul 22, 2026 | 162 |
| NCT06819891Moderately to Severely Active Crohns Disease · United States, Argentina, Australia and more | 3 | Recruiting | Dec 31, 2028 | 425 |
| NCT06819878Moderately to Severely Active Crohns Disease · United States, Argentina, Australia and more | 3 | Recruiting | Dec 31, 2028 | 600 |
| NCT06589986Moderately to Severely Active Ulcerative Colitis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 30, 2027 | 400 |
| NCT06588855Moderately to Severely Active Ulcerative Colitis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 29, 2026 | 350 |
| NCT05910528Crohn Disease · United States, Belgium, France and more | 2 | Active, not recruiting | Dec 31, 2026 | 21 |
| NCT04269538Healthy · Japan | 1 | Completed | Nov 11, 2020 | 16 |
| NCT04090411Moderate to Severe Ulcerative Colitis · United States, Australia, Belgium and more | 2 | Completed | Oct 25, 2022 | 246 |
| NCT02840721Colitis, Ulcerative · United States, Belgium, Italy and more | 2 | Completed | May 31, 2018 | 50 |
| NCT01989143Healthy · United States | 1 | Completed | Mar 2015 | 92 |
How it is read
Names in the registry
- “Afimkibart”, 13 entries
- “PF-06480605”, 5 entries
- “RO7790121”, 1 entry
- “Induction- PF-06480605 150 mg SC Q4W”, 1 entry
- “Induction- PF-06480605 450 mg SC Q4W”, 1 entry
Codes read as this program: PF06480605.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 7 studies
- Crohn Disease, 4 studies
- Dermatitis, Atopic, 2 studies
- Arthritis, Rheumatoid, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.